🐦 推特SerenityCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-30 14:52:06时区推断·⟳ 抓取 07-30 14:52:37·⚡ 决策 08-01 01:44:17 +1d10h·87.6 天前
FormFactor电话会称CPO测试收入加速并上调全年预期
FormFactor（FORM.US）电话会口径显示CPO相关系统收入加速，2026年CPO收入预期从此前1000万至2000万美元区间上沿进一步上修至全年显著超过2000万美元。
📄 原文Serenity@aleabitoreddit↗ 原文
Just some interesting takeaways from $FORM earnings call on CPO: Since they attributed systems revenue nearly doubled d…
不做 FormFactor（FORM.US）
同一Q2财报/CPO收入加速催化已在7月30日多次处理，当前只是社媒对电话会的二次摘录；没有新增订单、客户或未定价事实，且本轮未取得合格实时行情，不能补发ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FormFactor发布二季度财报及电话会材料，CPO收入加速的底层事实来自该公司财报沟通。
- Serenity摘录FORM电话会CPO口径并将其解读为CPO主题早期商业化信号，属于高影响力账号二次传播。
- 2026-07-30其它内部已处理事件库非一手同日已有FORM二季度业绩超预期、强展望、盘后股价大涨和财报材料等同簇事件被处理。市场反应:内部记录显示此前报道已提及盘后股价大涨约17%。
关键理由
- FormFactor（FORM.US）电话会口径显示CPO相关系统收入加速，2026年CPO收入预期从此前1000万至2000万美元区间上沿进一步上修至全年显著超过2000万美元。
- 该信息来自Q2财报电话会后的社媒二次整理，不是独立新增订单或新客户披露，且本系统已在同日处理过FORM二季度业绩和盘后大涨反应。
- CPO产业链确有中期景气验证，但当前信号只能确认主题早期商业化，不能给FORM或二阶标的形成新的、未被处理的可回测入场边界。
主要风险
- Serenity高影响力社媒扩散可能继续强化CPO主题短线情绪，但这属于传播动量而非新的公司级基本面增量。
- 行情工具本轮未返回FORM实时价，无法在已重复处理的财报催化上补出合格ENTER价格。
反向证据
- 做多前查反向 · 来源 search_case_library · 日期 2026-07-30 · 影响 invalidates
案例库命中多条同日FORM二季度业绩、强展望、盘后大涨和财报材料处理记录，说明当前推文不是新的独立催化。
检索:FORM.US search_case_library include_duplicates - 做多前查反向 · 来源 kb_search · 影响 none
内部KB检索服务超时，未能补到新的未传播增量。
检索:FormFactor FORM CPO co-packaged optics revenue 2026 earnings call - 做多前查反向 · 来源 query_modeling_kb · 影响 none
定量库支持CPO在2026年前后进入产业化早期，但并未给出本推文之外的FORM新增订单或二阶A/H股可交易敞口。
检索:CPO co-packaged optics optical engines lasers test equipment FormFactor FORM
工具调用 · 历史记录,结果未知(7 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- query_modeling_kb · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- supply_chain_lookup · 结果未知
- price_snapshot · 结果未知
原文全文
展开原文 · 1,685 字
Just some interesting takeaways from $FORM earnings call on CPO:
Since they attributed systems revenue nearly doubled due to: "accelerating growth in co-packaged optics or CPO".
Q1 2026: "we now expect 2026 CPO revenues to come in at the high end of the $10 million to $20 million range"
Q2 2026 (now): "expect to exceed that range by the end of the third quarter, and to significantly exceed the $20 million level for the year overall."
Management stated "We’re seeing some significant acceleration in this [CPO] business".
Q: CPO adoption outlook. Are we perhaps expecting the timeline to accelerate a little bit?
A: "What I would say is there’s acceleration here in the very short term." But management stated there's not a significant pull-in on timelines.
Citing production infrastructure (not just R&D) for:
- The growing volumes of CPO chips planned for later this year + test insertion for scale-up and scale-out switches.
- Seems like that CPO piece flows through $TSM COUPE [ likely maps to $NVDA CPO products] - "The CPO piece does flow through that 10% customer"
So now, test is ramping given management cited growing volumes of CPO chips.
"The rapid recent growth of our CPO business is an exciting development, which we believe represents the very early stages of widespread adoption of silicon photonics in the broader semiconductor industry"
TLDR: Fundamentally, CPO as a theme is very early, and should start to go brrr soon since it's starting to show up in earnings now (equipment/test players usually appear up first before optical engines / laser volumes ramp).
Personally once all the deleveraging stops, I think markets will start to care more.
Since they attributed systems revenue nearly doubled due to: "accelerating growth in co-packaged optics or CPO".
Q1 2026: "we now expect 2026 CPO revenues to come in at the high end of the $10 million to $20 million range"
Q2 2026 (now): "expect to exceed that range by the end of the third quarter, and to significantly exceed the $20 million level for the year overall."
Management stated "We’re seeing some significant acceleration in this [CPO] business".
Q: CPO adoption outlook. Are we perhaps expecting the timeline to accelerate a little bit?
A: "What I would say is there’s acceleration here in the very short term." But management stated there's not a significant pull-in on timelines.
Citing production infrastructure (not just R&D) for:
- The growing volumes of CPO chips planned for later this year + test insertion for scale-up and scale-out switches.
- Seems like that CPO piece flows through $TSM COUPE [ likely maps to $NVDA CPO products] - "The CPO piece does flow through that 10% customer"
So now, test is ramping given management cited growing volumes of CPO chips.
"The rapid recent growth of our CPO business is an exciting development, which we believe represents the very early stages of widespread adoption of silicon photonics in the broader semiconductor industry"
TLDR: Fundamentally, CPO as a theme is very early, and should start to go brrr soon since it's starting to show up in earnings now (equipment/test players usually appear up first before optical engines / laser volumes ramp).
Personally once all the deleveraging stops, I think markets will start to care more.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。